|
|
|
|
| | | | USD | EUR | GBP | JPY | 83.52 | 88.89 | 103.80 | 0.54 |
| | | | AED | AUD | CHF | CAD | 17.54 | 49.53 | 64.49 | 50.06 |
| | | | HKD | SAR | SGD | ZAR | 8.28 | 17.22 | 47.46 | 4.57 |
|
|
|
|
|
|
|
|
|
|
|
Industry :
|
Pharmaceuticals & Drugs
|
|
|
|
|
|
|
|
|
|
52-Week-High (Rs.)
|
155.45
|
|
|
|
|
|
|
* BSE PRICES
|
|
|
|
|
|
(Rs. in Million) | Particulars | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Audited / UnAudited | UnAudited | UnAudited | UnAudited | Audited | Net Sales | 422.05 | 491.19 | 404.23 | 465.95 | Total Expenditure | 463.61 | 568.19 | 494.90 | 526.40 | PBIDT (Excl OI) | -41.56 | -77.00 | -90.67 | -60.45 | Other Income | 134.44 | 98.66 | 96.95 | 80.13 | Operating Profit | 92.88 | 21.66 | 6.28 | 19.68 | Interest | 11.45 | 12.09 | 9.82 | 8.67 | Exceptional Items | 0 | 0 | -62.54 | 0 | PBDT | 81.43 | 9.57 | -66.08 | 11.01 | Depreciation | 20.53 | 23.53 | 24.25 | 23.31 | Profit Before Tax | 60.90 | -13.96 | -90.33 | -12.30 | Tax | 15.10 | -4.78 | -22.30 | 4.15 | Provisions and contingencies | 0 | 0 | 0 | 0 | Profit After Tax | 45.80 | -9.18 | -68.03 | -16.45 | Extraordinary Items | 0 | 0 | 0 | 0 | Prior Period Expenses | 0 | 0 | 0 | 0 | Other Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | Net Profit | 45.80 | -9.18 | -68.03 | -16.45 | Equity Capital | 498.86 | 498.86 | 498.87 | 498.87 | Face Value (IN RS) | 2 | 2 | 2 | 2 | Reserves | | | | | Calculated EPS | 0.18 | -0.04 | -0.27 | -0.07 | Calculated EPS (Annualised) | 0.73 | -0.15 | -1.09 | -0.26 | No of Public Share Holdings | 117,753,392.00 | 117,753,392.00 | 117,753,392.00 | 117,753,392.00 | % of Public Share Holdings | 47.21 | 47.21 | 47.21 | 47.21 | | | | | | PBIDTM% (Excl OI) | -9.85 | -15.68 | -22.43 | -12.97 | PBIDTM% | 22.01 | 4.41 | 1.55 | 4.22 | PBDTM% | 19.29 | 1.95 | -16.35 | 2.36 | PBTM% | 14.43 | -2.84 | -22.35 | -2.64 | PATM% | 10.85 | -1.87 | -16.83 | -3.53 | | Notes | Notes | Notes | Notes |
|
|
|
|
|
|